Patents by Inventor Heather L. Davis
Heather L. Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8574599Abstract: The invention relates methods and products for inducing mucosal immunity. In particular, the invention relates to the use of immunostimulatory oligonucleotides containing a CpG motif for inducing mucosal immunity. The CpG immunostimulatory oligonucleotides may be administered alone or in combination with antigen and/or with other adjuvants.Type: GrantFiled: May 21, 1999Date of Patent: November 5, 2013Assignee: Ottawa Hospital Research InstituteInventors: Michael J. McCluskie, Heather L. Davis
-
Patent number: 8202688Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.Type: GrantFiled: November 20, 2002Date of Patent: June 19, 2012Assignees: University of Iowa Research Foundation, Coley Pharmaceutical GmbH, Ottawa Health Research InstituteInventors: Heather L. Davis, Joachim Schorr, Arthur M. Krieg
-
Patent number: 7998492Abstract: The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, the subjects are those that are non-responsive to non-CpG therapy. Preferably, the subjects are treated with C class CpG immunostimulatory nucleic acids having a semi-soft backbone.Type: GrantFiled: October 29, 2003Date of Patent: August 16, 2011Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Navneet K. Ahluwalia, Susan M. Efler, Heather L. Davis, Jörg Vollmer
-
Publication number: 20110135605Abstract: The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, the subjects are those that are non-responsive to non-CpG therapy. Preferably, the subjects are treated with C class CpG immunostimulatory nucleic acids having semi-soft backbone.Type: ApplicationFiled: November 15, 2010Publication date: June 9, 2011Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Navneet K. Ahluwalia, Susan M. Efler, Heather L. Davis, Jörg Vollmer
-
Publication number: 20090155307Abstract: The invention involves methods and compositions of an immunostimulatory nucleic acid in oil-in-water emulsions for topical delivery. The compositions can be used to stimulate immune responses, particularly useful in the prevention and/or treatment of infectious disease and cancer.Type: ApplicationFiled: August 21, 2008Publication date: June 18, 2009Applicant: Coley Pharmaceutical Group, Ltd.Inventors: Heather L. Davis, Michael J. McCluskie
-
Patent number: 7488490Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.Type: GrantFiled: December 18, 2001Date of Patent: February 10, 2009Assignee: University of Iowa Research FoundationInventors: Heather L. Davis, Joachim Schorr, Arthur M. Krieg
-
Publication number: 20090017021Abstract: The invention relates to TLR ligand formulations that comprise immune stimulating complexes and their use in inducing innate immunity.Type: ApplicationFiled: April 17, 2008Publication date: January 15, 2009Applicants: Coley Pharmaceutical Group, Ltd., CSL LimitedInventors: Heather L. Davis, Michael J. McCluskie, Debra P. Drane
-
Publication number: 20040266719Abstract: The invention relates methods and products for inducing mucosal immunity. In particular, the invention relates to the use of immunostimulatory oligonucleotides containing a CpG motif for inducing mucosal immunity. The CpG immunostimulatory oligonucleotides may be administered alone or in combination with antigen and/or with other adjuvants.Type: ApplicationFiled: July 9, 2004Publication date: December 30, 2004Inventors: Michael J. McCluskie, Heather L. Davis
-
Publication number: 20040235770Abstract: The invention involves methods and compositions of an immunostimulatory nucleic acid in oil-in-water emulsions for topical delivery. The compositions can be used to stimulate immune responses, particularly useful in the prevention and/or treatment of infectious disease and cancer.Type: ApplicationFiled: April 1, 2004Publication date: November 25, 2004Applicant: Coley Pharmaceutical Group, Ltd.Inventors: Heather L. Davis, Michael J. McCluskie
-
Patent number: 6821957Abstract: The present invention shows that DNA vaccine vectors can be improved by removal of CpG-N motifs and optional addition of CpG-S motifs. In addition, for high and long-lasting levels of expression, the optimized vector should include a promoter/enhancer that is not down-regulated by the cytokines induced by the immunostimulatory CpG motifs. Vectors and methods of use for immununostimulation are provided herein. The invention also provides improved gene therapy vectors by determining the CpG-N and CpG-S motifs present in the construct, removing stimulatory CpG (CpG-S) motifs and/or inserting neutralizing CpG (CpG-N) motifs, thereby producing a nucleic acid construct providing enhanced expression of the therapeutic polypeptide. Methods of use for such vectors are also included herein.Type: GrantFiled: September 26, 2001Date of Patent: November 23, 2004Assignee: University of Iowa Research FoundationInventors: Arthur M. Krieg, Heather L. Davis, Tong Wu, Schorr Joachim
-
Publication number: 20040186067Abstract: The present invention shows that DNA vaccine vectors can be improved by removal of CpG-N motifs and optional addition of CpG-S motifs. In addition, for high and long-lasting levels of expression, the optimized vector should include a promoter/enhancer that is not down-regulated by the cytokines induced by the immunostimulatory CpG motifs. Vectors and methods of use for immunostimulation are provided herein. The invention also provides improved gene therapy vectors by determining the CpG-N and CpG-S motifs present in the construct, removing stimulatory CpG (CpG-S) motifs and/or inserting neutralizing CpG (CpG-N) motifs, thereby producing a nucleic acid construct providing enhanced expression of the therapeutic polypeptide. Methods of use for such vectors are also included herein.Type: ApplicationFiled: September 26, 2001Publication date: September 23, 2004Inventors: Arthur M. Krieg, Heather L. Davis, Tong Wu, Joachim Schorr
-
Publication number: 20030224010Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.Type: ApplicationFiled: May 9, 2003Publication date: December 4, 2003Applicants: Coley Pharmaceutical GmbH, University of Iowa Research Foundation, CPG Immunopharmaceuticals GMBH, Ottawa Health Research InstituteInventors: Heather L. Davis, Joachim Schorr, Arthur M. Krieg
-
Publication number: 20030091599Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.Type: ApplicationFiled: November 20, 2002Publication date: May 15, 2003Applicant: Coley Pharmaceutical GmbHInventors: Heather L. Davis, Joachim Schorr, Arthur M. Krieg
-
Publication number: 20020164341Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.Type: ApplicationFiled: December 18, 2001Publication date: November 7, 2002Applicant: Loeb Health Research Institute at the Ottawa HospitalInventors: Heather L. Davis, Joachim Schorr, Arthur M. Krieg
-
Patent number: 6406705Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.Type: GrantFiled: June 3, 1999Date of Patent: June 18, 2002Assignees: University of Iowa Research Foundation, Coley Pharmaceutical GmbH, Ottawa Health Research InstituteInventors: Heather L. Davis, Joachim Schorr, Arthur M. Krieg
-
Patent number: 6339068Abstract: The present invention shows that DNA vaccine vectors can be improved by removal of CpG-N motifs and optional addition of CpG-S motifs. In addition, for high and long-lasting levels of expression, the optimized vector should include a promoter/enhancer that is not down-regulated by the cytokines induced by the immunostimulatory CpG motifs. Vectors and methods of use for immunostimulation are provided herein. The invention also provides improved gene therapy vectors by determining the CpG-N and CpG-S motifs present in the construct, removing stimulatory CpG (CpG-S) motifs and/or inserting neutralizing CpG (CpG-N) motifs, thereby producing a nucleic acid construct providing enhanced expression of the therapeutic polypeptide. Methods of use for such vectors are also included herein.Type: GrantFiled: May 20, 1998Date of Patent: January 15, 2002Assignees: University of Iowa Research Foundation, Loeb Health Research Institute at the Ottawa Hospital, Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Heather L. Davis, Tong Wu, Joachim Schorr
-
Publication number: 20010044416Abstract: The invention relates to methods and products for inducing an immune response using immunostimulatory nucleic acids. In particular the immunostimulatory nucleic acids preferentially induce a Th2 immune response. The invention is useful for treating and preventing disorders associated with a Th1 immune response or for creating a Th2 environment for treating disorders that are sensitive to Th2 immune responses.Type: ApplicationFiled: January 22, 2001Publication date: November 22, 2001Inventors: Michael J. McCluskie, Heather L. Davis
-
Patent number: 6180614Abstract: The present invention relates to methods of immunization of aquaculture species by introducing DNA expression systems into the aquaculture species. Such DNA expression systems preferably include DNA sequences encoding polypeptides of pathogens of species of aquaculture. The present invention also relates to methods of administration of DNA expression systems into aquaculture. Such methods include injection, spray, and immersion techniques. The methods of this invention are useful for prophylactic vaccination or therapeutic immunization of fin-fish, shellfish, or other aquatic animals against infectious diseases.Type: GrantFiled: July 14, 1998Date of Patent: January 30, 2001Assignee: Loeb Health Research Institute at The Ottawa HospitalInventor: Heather L. Davis
-
Patent number: 5780448Abstract: The present invention relates to methods of immunization of aquaculture species by introducing DNA expression systems into the aquaculture species. Such DNA expression systems preferably include DNA sequences encoding polypeptides of pathogens of species of aquaculture. The present invention also relates to methods of administration of DNA expression systems into aquaculture. Such methods include injection, spray, and immersion techniques. The methods of this invention are useful for prophylactic vaccination or therapeutic immunization of fin-fish, shellfish, or other aquatic animals against infectious diseases.Type: GrantFiled: November 4, 1996Date of Patent: July 14, 1998Assignee: Ottawa Civic Hospital Loeb ResearchInventor: Heather L. Davis